Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2014

BioVersys, SARomics to Battle Drug-Resistant Infections

  • BioVersys, a spinoff biopharma company from the ETH Zurich focused on antibiotic resistance, is teaming up with Swedish firm SARomics Biostructures to take on antimicrobial resistance as part of an international project supported by the Eurostars initiative, which will be financing part of it through a grant.

    The aim of the SARTRIC project is to find a way to block the transcriptional activation of resistance genes with small molecules so that drugs that are already on the market will work on the resistant diseases again. The two firms will pool their resources to turn initial hit molecules into lead molecules that would be good candidates for preclinical testing.

    BioVersys and SARomics believe their specializations and expertise are complementary and should work together well. "It is a great pleasure to see the synergies between our two companies bearing fruit," BioVersys' CSO Marcel Tigges said in a statement.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »